Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy?
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider...
Posts Tagged ‘Is FOLD A Good Investment Right Now?’
Here is What Hedge Funds Think About Amicus Therapeutics, Inc. (FOLD)
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade.
Is FOLD Stock A Buy or Sell?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first.
Is FOLD A Good Stock To Buy Now?
At Insider Monkey, we pore over the filings of nearly 817 top investment firms every quarter, a process we have now completed for the latest reporting period.
Is Amicus Therapeutics, Inc. (FOLD) Going to Burn These Hedge Funds?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file ...
Did Hedge Funds Make The Right Call On Amicus Therapeutics, Inc. (FOLD)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Amicus Therapeutics, Inc. (FOLD): Hedge Funds Folding Their Hands
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Funds Have Never Been This Bullish On Amicus Therapeutics, Inc. (FOLD)
We hate to say this but, we told you so.
2019 Review: Most Favored Hedge Fund Stocks vs. Amicus Therapeutics, Inc. (FOLD)
2018's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about...
Hedge Funds Cashed Out Of Amicus Therapeutics, Inc. (FOLD) Too Early
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November.
Were Hedge Funds Right About Souring On Amicus Therapeutics, Inc. (FOLD)?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing.
Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy?
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could...
Amicus Therapeutics, Inc. (FOLD) Hedge Funds Are Snapping Up
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed...
Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy?
Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to...
Is Redmile Group Right to Bet on Array Biopharma Inc (ARRY), Amicus Therapeutics, Inc. (FOLD) & Two Other Stocks?
Despite of all the negative sentiment looming around them, hedge funds had a pretty solid run for much of this year, generating positive returns for seven or eight consecutive...
Big Bet on Sarepta Therapeutics Inc (SRPT) Lifts Perceptive Advisors’ Q3 Returns; See How Other Investments Performed
Joseph Edelman's Perceptive Advisors is a fund that has an equity portfolio worth $1.44 billion as of the end of June, with over 80% of it being invested in healthcare stocks.
